6 days Ago By ABMN Staff
Russell Investments Group Ltd. boosted its stake in AtriCure, Inc. ( NASDAQ:ATRC – Free Report ) by 8.
5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 156,649 shares of the medical device company’s stock after buying an additional 12,212 shares during the period. Russell Investments Group Ltd.
owned 0.32% of AtriCure worth $4,787,000 at the end of the most recent reporting period. Several other large investors have also bought and sold shares of the company.
Blue Trust Inc. lifted its stake in shares of AtriCure by 1.8% in the 4th quarter.
Blue Trust Inc. now owns 14,751 shares of the medical device company’s stock valued at $414,000 after purchasing an additional 265 shares during the period. Perkins Capital Management Inc.
lifted its position in AtriCure by 1.3% during the fourth quarter. Perkins Capital Management Inc.
now owns 30,350 shares of the medical device company’s stock valued at $927,000 after buying an additional 400 shares during the period. Truist Financial Corp grew its position in shares of AtriCure by 2.6% in the 4th quarter.
Truist Financial Corp now owns 15,717 shares of the medical device company’s stock worth $480,000 after buying an additional 403 shares during the period. Franklin Resources Inc. increased its stake in shares of AtriCure by 0.
9% in the 3rd quarter. Franklin Resources Inc. now owns 56,843 shares of the medical device company’s stock worth $1,569,000 after acquiring an additional 484 shares in the last quarter.
Finally, LPL Financial LLC lifted its position in AtriCure by 5.4% during the 4th quarter. LPL Financial LLC now owns 11,465 shares of the medical device company’s stock valued at $350,000 after acquiring an additional 584 shares during the period.
99.11% of the stock is owned by institutional investors. AtriCure Stock Up 1.
7 % Shares of AtriCure stock opened at $32.62 on Tuesday. The company has a quick ratio of 2.
62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13.
AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.
11. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -34.
34 and a beta of 1.65. The company’s 50 day moving average is $35.
84 and its 200 day moving average is $34.34. Wall Street Analyst Weigh In Get Our Latest Research Report on AtriCure Insider Transactions at AtriCure In other AtriCure news, Director Karen Prange sold 6,100 shares of the firm’s stock in a transaction dated Wednesday, March 5th.
The stock was sold at an average price of $38.12, for a total value of $232,532.00.
Following the transaction, the director now directly owns 17,828 shares of the company’s stock, valued at approximately $679,603.36. This trade represents a 25.
49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink . Company insiders own 3.
20% of the company’s stock. About AtriCure ( Free Report ) AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.
Featured Stories Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter ..
